Management of hypocalcemic effects of WR2721 administered on a daily times five schedule with cisplatin and radiation therapy

Scott Wadler, Hilda Haynes-Lewis, Jonathan J. Beitler, Gary Goldberg, James F. Holland, Howard Hochster, Howard Bruckner, John Mandeli, Harriet O. Smith, Carolyn Runowicz

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Purpose: To determine the effects of the chemoprotective agent, WR2721, administered on a daily × 5 schedule with cisplatin and radiation therapy, on calcium and parathyroid hormone (PTH) levels. Patients and Methods: Twenty women with cervical cancer were enrolled in a clinical trial to determine the maximal safe dose of WR2721 plus radiation therapy and cisplatin on a novel daily × 5 schedule. Detailed studies of the effects of WR2721 on calcium and PTH levels were initiated after a patient developed symptomatic hypocalcemia. Results: Treatment with WR2721 resulted in a rapid decline in serum PTH levels within 4 hours, which fell below the lower limits of normal at 24 hours, then returned to within normal limits at 48 hours. In contrast, serum levels of ionized calcium were not affected acutely, and declined by only 7% within 24 hours. How-ever, this small decrease persisted for the 5 days of treatment. Hypocalcemic effects were successfully managed with oral calcium carbonate and calcitriol supplements. In one patient, particularly sensitive to the effects of WR2721, serum levels of ionized calcium decreased to less than 3.0 mg/dL despite oral calcium supplements. Conclusion: The effects of WR2721 on serum ionized calcium levels are mediated by direct inhibition of PTH activity; other effects such as inhibition of renal tubular calcium reabsorption cannot be excluded. We recommend that patients treated with WR2721, cisplatin, and radiation therapy receive routine oral calcium and calcitriol supplementation and that serum ionized calcium levels be monitored frequently.

Original languageEnglish (US)
Pages (from-to)1517-1522
Number of pages6
JournalJournal of Clinical Oncology
Volume11
Issue number8
StatePublished - 1993

Fingerprint

Cisplatin
Appointments and Schedules
Radiotherapy
Calcium
Parathyroid Hormone
Serum
Calcitriol
Hypocalcemia
Calcium Carbonate
Uterine Cervical Neoplasms
Clinical Trials
Kidney
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Wadler, S., Haynes-Lewis, H., Beitler, J. J., Goldberg, G., Holland, J. F., Hochster, H., ... Runowicz, C. (1993). Management of hypocalcemic effects of WR2721 administered on a daily times five schedule with cisplatin and radiation therapy. Journal of Clinical Oncology, 11(8), 1517-1522.

Management of hypocalcemic effects of WR2721 administered on a daily times five schedule with cisplatin and radiation therapy. / Wadler, Scott; Haynes-Lewis, Hilda; Beitler, Jonathan J.; Goldberg, Gary; Holland, James F.; Hochster, Howard; Bruckner, Howard; Mandeli, John; Smith, Harriet O.; Runowicz, Carolyn.

In: Journal of Clinical Oncology, Vol. 11, No. 8, 1993, p. 1517-1522.

Research output: Contribution to journalArticle

Wadler, S, Haynes-Lewis, H, Beitler, JJ, Goldberg, G, Holland, JF, Hochster, H, Bruckner, H, Mandeli, J, Smith, HO & Runowicz, C 1993, 'Management of hypocalcemic effects of WR2721 administered on a daily times five schedule with cisplatin and radiation therapy', Journal of Clinical Oncology, vol. 11, no. 8, pp. 1517-1522.
Wadler, Scott ; Haynes-Lewis, Hilda ; Beitler, Jonathan J. ; Goldberg, Gary ; Holland, James F. ; Hochster, Howard ; Bruckner, Howard ; Mandeli, John ; Smith, Harriet O. ; Runowicz, Carolyn. / Management of hypocalcemic effects of WR2721 administered on a daily times five schedule with cisplatin and radiation therapy. In: Journal of Clinical Oncology. 1993 ; Vol. 11, No. 8. pp. 1517-1522.
@article{2a8f9218d62e421a8dd7958806be06ce,
title = "Management of hypocalcemic effects of WR2721 administered on a daily times five schedule with cisplatin and radiation therapy",
abstract = "Purpose: To determine the effects of the chemoprotective agent, WR2721, administered on a daily × 5 schedule with cisplatin and radiation therapy, on calcium and parathyroid hormone (PTH) levels. Patients and Methods: Twenty women with cervical cancer were enrolled in a clinical trial to determine the maximal safe dose of WR2721 plus radiation therapy and cisplatin on a novel daily × 5 schedule. Detailed studies of the effects of WR2721 on calcium and PTH levels were initiated after a patient developed symptomatic hypocalcemia. Results: Treatment with WR2721 resulted in a rapid decline in serum PTH levels within 4 hours, which fell below the lower limits of normal at 24 hours, then returned to within normal limits at 48 hours. In contrast, serum levels of ionized calcium were not affected acutely, and declined by only 7{\%} within 24 hours. How-ever, this small decrease persisted for the 5 days of treatment. Hypocalcemic effects were successfully managed with oral calcium carbonate and calcitriol supplements. In one patient, particularly sensitive to the effects of WR2721, serum levels of ionized calcium decreased to less than 3.0 mg/dL despite oral calcium supplements. Conclusion: The effects of WR2721 on serum ionized calcium levels are mediated by direct inhibition of PTH activity; other effects such as inhibition of renal tubular calcium reabsorption cannot be excluded. We recommend that patients treated with WR2721, cisplatin, and radiation therapy receive routine oral calcium and calcitriol supplementation and that serum ionized calcium levels be monitored frequently.",
author = "Scott Wadler and Hilda Haynes-Lewis and Beitler, {Jonathan J.} and Gary Goldberg and Holland, {James F.} and Howard Hochster and Howard Bruckner and John Mandeli and Smith, {Harriet O.} and Carolyn Runowicz",
year = "1993",
language = "English (US)",
volume = "11",
pages = "1517--1522",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "8",

}

TY - JOUR

T1 - Management of hypocalcemic effects of WR2721 administered on a daily times five schedule with cisplatin and radiation therapy

AU - Wadler, Scott

AU - Haynes-Lewis, Hilda

AU - Beitler, Jonathan J.

AU - Goldberg, Gary

AU - Holland, James F.

AU - Hochster, Howard

AU - Bruckner, Howard

AU - Mandeli, John

AU - Smith, Harriet O.

AU - Runowicz, Carolyn

PY - 1993

Y1 - 1993

N2 - Purpose: To determine the effects of the chemoprotective agent, WR2721, administered on a daily × 5 schedule with cisplatin and radiation therapy, on calcium and parathyroid hormone (PTH) levels. Patients and Methods: Twenty women with cervical cancer were enrolled in a clinical trial to determine the maximal safe dose of WR2721 plus radiation therapy and cisplatin on a novel daily × 5 schedule. Detailed studies of the effects of WR2721 on calcium and PTH levels were initiated after a patient developed symptomatic hypocalcemia. Results: Treatment with WR2721 resulted in a rapid decline in serum PTH levels within 4 hours, which fell below the lower limits of normal at 24 hours, then returned to within normal limits at 48 hours. In contrast, serum levels of ionized calcium were not affected acutely, and declined by only 7% within 24 hours. How-ever, this small decrease persisted for the 5 days of treatment. Hypocalcemic effects were successfully managed with oral calcium carbonate and calcitriol supplements. In one patient, particularly sensitive to the effects of WR2721, serum levels of ionized calcium decreased to less than 3.0 mg/dL despite oral calcium supplements. Conclusion: The effects of WR2721 on serum ionized calcium levels are mediated by direct inhibition of PTH activity; other effects such as inhibition of renal tubular calcium reabsorption cannot be excluded. We recommend that patients treated with WR2721, cisplatin, and radiation therapy receive routine oral calcium and calcitriol supplementation and that serum ionized calcium levels be monitored frequently.

AB - Purpose: To determine the effects of the chemoprotective agent, WR2721, administered on a daily × 5 schedule with cisplatin and radiation therapy, on calcium and parathyroid hormone (PTH) levels. Patients and Methods: Twenty women with cervical cancer were enrolled in a clinical trial to determine the maximal safe dose of WR2721 plus radiation therapy and cisplatin on a novel daily × 5 schedule. Detailed studies of the effects of WR2721 on calcium and PTH levels were initiated after a patient developed symptomatic hypocalcemia. Results: Treatment with WR2721 resulted in a rapid decline in serum PTH levels within 4 hours, which fell below the lower limits of normal at 24 hours, then returned to within normal limits at 48 hours. In contrast, serum levels of ionized calcium were not affected acutely, and declined by only 7% within 24 hours. How-ever, this small decrease persisted for the 5 days of treatment. Hypocalcemic effects were successfully managed with oral calcium carbonate and calcitriol supplements. In one patient, particularly sensitive to the effects of WR2721, serum levels of ionized calcium decreased to less than 3.0 mg/dL despite oral calcium supplements. Conclusion: The effects of WR2721 on serum ionized calcium levels are mediated by direct inhibition of PTH activity; other effects such as inhibition of renal tubular calcium reabsorption cannot be excluded. We recommend that patients treated with WR2721, cisplatin, and radiation therapy receive routine oral calcium and calcitriol supplementation and that serum ionized calcium levels be monitored frequently.

UR - http://www.scopus.com/inward/record.url?scp=0027281672&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027281672&partnerID=8YFLogxK

M3 - Article

VL - 11

SP - 1517

EP - 1522

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 8

ER -